Section 4 of 6
Clinical evidence
118 evidence topics · 30 sources
Study summaries
PEAK
Objective
Randomized comparison after prior imatinib
Location and study date
Part 1 update cutoff
Study design
Open-label international study and randomization
Crossover after centrally confirmed progression
Eligibility criteria
Histologic diagnosis and disease extent
Prior therapy for the randomized comparison
Treatment
Selected combination dose
Control-arm daily dose
| Treatment | Daily dose, mg |
|---|---|
| Sunitinib | “37.5” |
Study outcomes
Rationale for using BICR-assessed progression-free survival as the primary endpoint
Primary and key secondary endpoints
| Endpoint role | Endpoint |
|---|---|
| Primary | “Progression Free Survival per BICR” |
| Key secondary | “Objective Response Rate per BICR” |
| Key secondary | “Overall Survival” |
Statistical analysis description
Number of participants (Planned and analyzed)
Planned enrollment in the randomized part
Part 1 treated population
| Population | Participants |
|---|---|
| Part 1 | “42” |
Description of analysis sets
Summary
The pivotal response analysis reports 204 participants assigned to the combination and 209 assigned to sunitinib. The safety presentation uses 204 and 208 participants, respectively. These denominators should not be interchanged.
Part 1 safety analysis set
Full statistical analysis plan
No evidence found.
Results
Participant disposition
Summary
One participant assigned to sunitinib did not receive treatment. In the Part 1 update, 31 of 42 participants had discontinued and 11 remained on study treatment.
Baseline characteristics
Pivotal population age
| Characteristic | Value |
|---|---|
| Median age and range, years | “63 (30-88)” |
Efficacy results
PEAK phase 3: objective response
PEAK phase 3: overall survival
Progression on subsequent therapy: endpoint definition
Progression on subsequent therapy: reported results
| Measure | Value |
|---|---|
| Combination-arm median, months | “not reached” |
| Sunitinib-arm median, months | “21” |
| Hazard ratio | “0.57” |
| 95% confidence interval | “0.41-0.78” |
PEAK Part 1: subgroup with one prior treatment
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Study limitations
Summary
PEAK was open-label, although progression-free survival was assessed by blinded independent central review. Crossover was permitted after centrally confirmed progression, and overall-survival results remained immature. The randomized comparison required prior imatinib only and excluded PDGFR-driven and succinate dehydrogenase-deficient disease. Part 1 subgroup results should not be treated as randomized estimates.
SARC044
Objective
Safety and efficacy of combination treatment
Location and study date
Participating U.S. locations
| Location | Reported site location |
|---|---|
| Massachusetts | “Boston, MA, USA” |
| Pennsylvania | “Philadelphia, PA, USA” |
| Oregon | “Portland, OR, USA” |
| Florida | “Miami, FL, USA” |
Study design
Eligibility criteria
Treatment
Bezuclastinib lead-in and added sunitinib
Study outcomes
Rationale for using progression-free survival as the primary endpoint
Primary endpoint and planned patient-reported outcome instrument
| Measure | Reported measure |
|---|---|
| Primary endpoint | “mPFS” |
| Patient-reported outcome instrument | “EORTC QLQ-C30” |
Regulatory context for progression-free survival
Study-specific endpoint justification
No evidence found.
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Summary
The design used a one-sample log-rank calculation with a one-sided 5% significance level. Thirty-five evaluable participants provided 83% power for an assumed median progression-free survival of 6.5 months compared with a 4-month historical benchmark. This is a historical-control calculation, not a randomized comparison.
Statistical planning assumptions
| Parameter | Value |
|---|---|
| Statistical test | “one-sample log-rank test” |
| One-sided significance level | “5%” |
| Power | “83%” |
| Assumed median progression-free survival, months | “6.5” |
| Historical-control median progression-free survival, months | “4” |
Results
Participant disposition
Baseline characteristics
No evidence found.
Efficacy results
No evidence found.
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
No evidence found.
Study limitations
Summary
SARC044 is a single-arm, open-label phase 2 study with planned enrollment of up to 40 participants. Its statistical comparison uses a historical progression-free-survival benchmark rather than a concurrently randomized control. Eligibility primarily specifies KIT exon 9- or 11-mutant GIST, with other primary KIT mutations considered case by case. The enrollment-completion announcement does not establish efficacy or safety results.
INTRIGUE
Objective
Location and study date
International study sites
| Measure | Number |
|---|---|
| Sites | “122”View highlighted excerpt for this quote |
| Countries | “22”View highlighted excerpt for this quote |
Final overall-survival data cutoff
Study design
Eligibility criteria
Treatment
Randomized treatment doses
| Treatment | Oral dose |
|---|---|
| Ripretinib | “150 mg once daily”View highlighted excerpt for this quote |
| Sunitinib | “50 mg once daily”View highlighted excerpt for this quote |
Study outcomes
Rationale for using progression-free survival as the primary endpoint
Primary and key secondary endpoints
| Endpoint role | Endpoint |
|---|---|
| Primary | “progression-free survival”View highlighted excerpt for this quote |
| Key secondary | “objective response rate”View highlighted excerpt for this quote |
| Key secondary | “overall survival”View highlighted excerpt for this quote |
Regulatory context for progression-free survival
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Summary
Efficacy analyses used the intention-to-treat population. Safety analyses included participants who received at least one dose. The testing hierarchy evaluated progression-free survival, then response rate, then overall survival, with KIT exon 11 analyses preceding overall-population analyses. Failure of the primary comparison meant subsequent statistical comparisons were not confirmatory.
Reported analysis populations
Results
Participant disposition
Randomized treatment allocation
| Treatment | Participants |
|---|---|
| Ripretinib | “226”View highlighted excerpt for this quote |
| Sunitinib | “227”View highlighted excerpt for this quote |
Baseline characteristics
Overall baseline characteristics
| Characteristic | Value |
|---|---|
| Median age, years | “60”View highlighted excerpt for this quote |
| Male participants, percent | “62.0%”View highlighted excerpt for this quote |
Efficacy results
Primary progression-free-survival comparison
Overall-population progression-free survival
| Measure | Ripretinib | Sunitinib |
|---|---|---|
| Median progression-free survival, months | “8.0”View highlighted excerpt for this quote | “8.3”View highlighted excerpt for this quote |
Final overall-survival analysis
| Comparison | Median overall survival |
|---|---|
| Ripretinib versus sunitinib | “35.5 v 31.5 months”View highlighted excerpt for this quote |
Health-related quality of life and patient-reported outcomes
Patient-reported tolerability with ripretinib versus sunitinib
Safety results
Grade 3 or 4 treatment-emergent adverse events
| Measure | Ripretinib | Sunitinib |
|---|---|---|
| Participants with events | “41.3%”View highlighted excerpt for this quote | “65.6%”View highlighted excerpt for this quote |
Study limitations
Summary
The open-label study did not show superiority of ripretinib for its primary progression-free-survival comparison. Safety percentages describe treatment-emergent events and should not be equated with treatment-related-event percentages from other trials. Neither randomized arm contained bezuclastinib.
A6181004
Objective
Anticancer activity assessment
Location and study date
Registry-reported study dates
| Milestone | Date as recorded |
|---|---|
| Study start | “1/12/2003” |
| Last data collection | “1/05/2008” |
Study design
Eligibility criteria
Prior treatment requirement
Treatment
Sunitinib once-daily oral starting dose
Intermittent treatment schedule
Study outcomes
Rationale for using time to tumor progression as the primary endpoint
Regulatory distinction between progression and progression-free survival
Statistical analysis description
Number of participants (Planned and analyzed)
Randomized population
| Population | Participants |
|---|---|
| Overall | “312”View highlighted excerpt for this quote |
Description of analysis sets
Reported analysis approaches
“Intention-to-treat” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“modified intention-to-treat” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“per-protocol” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Detailed analysis-set definitions
“Analysed study populations included intention-to-treat (ITT; all patients randomised to treatment), modified ITT (all ITT patients with disease progression on imatinib confirmed by central radiology laboratory), and per-protocol (all patients who received at least one dose of assigned study treatment).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“ITT data are presented for efficacy and per-protocol data for safety; modified ITT data are discussed where relevant.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Results
Participant disposition
Summary
The trial was unblinded early after a planned interim analysis showed a longer time to progression with sunitinib.
Randomized treatment allocation
| Treatment | Participants |
|---|---|
| Sunitinib | “207”View highlighted excerpt for this quote |
| Placebo | “105”View highlighted excerpt for this quote |
Baseline characteristics
Balance between randomized groups and prior imatinib exposure
“Between December, 2003, and January, 2005, 312 patients were enrolled from 56 centres in 11 countries and were randomised to receive blinded sunitinib (n=207) or placebo (n=105).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“All characteristics were well balanced between the groups. The most common metastatic sites were the liver, peritoneum, and mesentery.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The sunitinib and placebo groups were also similar in terms of median maximum dose, median daily dose (503 mg vs 485 mg), and median cumulative dose (367 400 mg vs 376 400 mg) of previous imatinib therapy, as well as in other aspects of treatment history.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Efficacy results
Time to tumor progression
| Measure | Sunitinib | Placebo |
|---|---|---|
| Median, weeks | “27.3”View highlighted excerpt for this quote | “6.4”View highlighted excerpt for this quote |
Treatment effect on time to progression
| Measure | Value |
|---|---|
| Hazard ratio | “0.33”View highlighted excerpt for this quote |
| P value | “p<0.0001”View highlighted excerpt for this quote |
Overall survival with crossover permitted
“Despite the availability of the option to cross over, overall survival obtained with initial sunitinib treatment was better that that obtained with placebo (figure 4; HR 0·49, 95% CI 0·29–0·83; p=0·007)” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“the trial was unblinded early when a planned interim analysis showed significantly longer time to tumour progression with sunitinib” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Common treatment-related adverse events
Study limitations
Summary
The randomized trial was unblinded early after its planned interim analysis. Its primary endpoint was time to tumor progression rather than progression-free survival, which also counts deaths. The comparison was sunitinib against placebo, not bezuclastinib plus sunitinib against sunitinib.
05-177
Objective
Antitumor activity on a continuous schedule
Location and study date
No evidence found.
Study design
Eligibility criteria
Histologic diagnosis and suitability for standard therapy
Treatment
Summary
Participants were randomized to morning or evening administration of continuous daily sunitinib. This was a comparison of administration times, not of sunitinib against another drug.
Study outcomes
Rationale for using clinical benefit rate as the primary endpoint
Summary
The primary clinical benefit rate combined complete responses, partial responses, and stable disease lasting at least 24 weeks.
Regulatory context for interpreting stable disease
Statistical analysis description
Number of participants (Planned and analyzed)
Planned and treated populations
| Population | Participants |
|---|---|
| Planned | “61”View highlighted excerpt for this quote |
| Treated | “Sixty”View highlighted excerpt for this quote |
| Per dosing-time group | “30”View highlighted excerpt for this quote |
Description of analysis sets
Confidence interval accompanying the clinical benefit rate
Detailed analysis-set definitions
No evidence found.
Results
Participant disposition
Study completion
| Disposition | Participants |
|---|---|
| Completed the study | “26”View highlighted excerpt for this quote |
Baseline characteristics
No evidence found.
Efficacy results
Clinical benefit and overall survival
| Outcome | Value |
|---|---|
| Clinical benefit rate | “53%”View highlighted excerpt for this quote |
| Median overall survival | “107 weeks”View highlighted excerpt for this quote |
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Severity of most adverse events
Study limitations
Summary
The study treated 60 participants and was open-label. Randomization compared morning and evening dosing rather than continuous dosing against the intermittent schedule or against another therapy. The clinical benefit endpoint included prolonged stable disease, which is not equivalent to objective tumor response.
PLX121-01
Objective
Location and study date
Study design
Summary
The monotherapy and sunitinib-combination cohorts used nonrandomized 3+3 dose escalation.
Eligibility criteria
Age and performance-status thresholds
| Criterion | Value |
|---|---|
| Minimum age, years | “18”View highlighted excerpt for this quote |
| ECOG performance status | “0 to 2”View highlighted excerpt for this quote |
Treatment
Summary
The early-trial recommended phase 2 dose was PLX9486 1000 mg daily, combined with sunitinib 25 or 37.5 mg daily in continuous 28-day cycles.
Recommended phase 2 dose
| Drug | Daily dose, mg |
|---|---|
| PLX9486 | “1000”View highlighted excerpt for this quote |
Study outcomes
Rationale for using maximum tolerated dose as the primary endpoint
Not applicable.
Statistical analysis description
Number of participants (Planned and analyzed)
Unique enrolled population
| Population | Participants |
|---|---|
| PLX9486-naive participants | “39”View highlighted excerpt for this quote |
| Participants with GIST | “35”View highlighted excerpt for this quote |
Combination efficacy cohort
Description of analysis sets
Summary
Sample sizes reflected clinical considerations. Response intervals used exact binomial methods, and survival analyses used Kaplan-Meier methods.
Time-to-event analysis method
Results
Participant disposition
Summary
Three monotherapy participants were reenrolled in the extension, producing a safety population of 18 without increasing unique enrollment.
Combination-extension safety population
| Population | Participants |
|---|---|
| Including reenrolled participants | “18”View highlighted excerpt for this quote |
Baseline characteristics
Baseline age and sex
| Characteristic | Value |
|---|---|
| Median age, years | “57”View highlighted excerpt for this quote |
| Male participants, percent | “56.4%”View highlighted excerpt for this quote |
Efficacy results
PLX9486 plus sunitinib phase 1b/2a: efficacy
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Combination dose-limiting toxicity and commonly reported adverse events
Study limitations
Summary
The combination efficacy cohort included 15 PLX9486-naive participants. Nonrandomized treatment assignment, small sample size, and disease heterogeneity limit comparative interpretation.